Evidence map›Paper›PMID 38846068›Full record

ArticleEClinicalMedicine2024

Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review.

Manasvi Singh, Ashish Kumar, Narendra N Khanna, John R Laird, Andrew Nicolaides, Gavino Faa, Amer M Johri, Laura E Mantella, Jose Fernandes E Fernandes, Jagjit S Teji and 21 more

Abstract readScoping Review
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Artificial intelligence in clinical genetics: Current practice and attitudes among the clinical genetics workforce.Genetics in medicine : official journal of the American College of Medical Genetics · 2026
    Article
  8. Foundation models for cardiovascular diseases and medicine.European heart journal. Digital health · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Current adoption of the Prosthodontic Diagnostic Index for clinical care-A cross-sectional survey study.Journal of prosthodontics : official journal of the American College of Prosthodontists · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Manasvi SinghStroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, 95661, USA.
Ashish KumarBennett University, 201310, Greater Noida, India.
Narendra N KhannaDepartment of Cardiology, Indraprastha APOLLO Hospitals, New Delhi, 110001, India.
John R LairdHeart and Vascular Institute, Adventist Health St. Helena, St Helena, CA, 94574, USA.
Andrew NicolaidesVascular Screening and Diagnostic Centre and University of Nicosia Medical School, Cyprus.
Gavino FaaDepartment of Pathology, University of Cagliari, Cagliari, Italy.
Amer M JohriDepartment of Medicine, Division of Cardiology, Queen's University, Kingston, Canada.
Laura E MantellaDepartment of Medicine, Division of Cardiology, University of Toronto, Toronto, Canada.
Jose Fernandes E FernandesDepartment of Vascular Surgery, University of Lisbon, Lisbon, Portugal.
Jagjit S TejiAnn and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA.
Narpinder SinghDepartment of Food Science and Technology, Graphic Era Deemed to Be University, Dehradun, Uttarakhand, 248002, India.
Mostafa M FoudaDepartment of Electrical and Computer Engineering, Idaho State University, Pocatello, ID, 83209, USA.
Rajesh SinghDepartment of Research and Innovation, Uttaranchal Institute of Technology, Uttaranchal University, Dehradun, 248007, India.
Aditya SharmaDivision of Cardiovascular Medicine, University of Virginia, Charlottesville, 22901, VA, USA.
George KitasAcademic Affairs, Dudley Group NHS Foundation Trust, DY1, Dudley, UK.
Vijay RathoreNephrology Department, Kaiser Permanente, Sacramento, CA, 95823, USA.
Inder M SinghStroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, 95661, USA.
Kalyan TadepalliJio Artificial Intelligence, Centre of Excellence, India.
Mustafa Al-MainiAllergy, Clinical Immunology and Rheumatology Institute, Toronto, ON, L4Z 4C4, Canada.
Esma R IsenovicDepartment of Radiobiology and Molecular Genetics, National Institute of The Republic of Serbia, University of Belgrade, 110010, Serbia.
Seemant ChaturvediDepartment of Neurology & Stroke Program, University of Maryland, Baltimore, MD, USA.
Deepak GargSR University, Warangal, Telangana, India.
Kosmas I ParaskevasDepartment of Vascular Surgery, Central Clinic of Athens, Athens, Greece.
Dimitri P MikhailidisDepartment of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK.
Vijay ViswanathanMV Diabetes Centre, Royapuram, Chennai, Tamil Nadu, 600013, India.
Manudeep K KalraDepartment of Radiology, Harvard Medical School, Boston, MA, USA.
Zoltan RuzsaInvasive Cardiology Division, University of Szeged, Szeged, Hungary.
Luca SabaDepartment of Radiology, Azienda Ospedaliero Universitaria, 40138, Cagliari, Italy.
Andrew F LaineDepartments of Biomedical and Radiology, Columbia University, New York, NY, USA.
Deepak L BhattIcahn School of Medicine, Mount Sinai, NY, USA.
Jasjit S SuriStroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, 95661, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The field of precision medicine endeavors to transform the healthcare industry by advancing individualised strategies for diagnosis, treatment modalities, and predictive assessments. This is achieved by utilizing extensive multidimensional biological datasets encompassing diverse components, such as an individual's genetic makeup, functional attributes, and environmental influences. Artificial intelligence (AI) systems, namely machine learning (ML) and deep learning (DL), have exhibited remarkable efficacy in predicting the potential occurrence of specific cancers and cardiovascular diseases (CVD). Methods: We conducted a comprehensive scoping review guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework. Our search strategy involved combining key terms related to CVD and AI using the Boolean operator AND. In August 2023, we conducted an extensive search across reputable scholarly databases including Google Scholar, PubMed, IEEE Xplore, ScienceDirect, Web of Science, and arXiv to gather relevant academic literature on personalised medicine for CVD. Subsequently, in January 2024, we extended our search to include internet search engines such as Google and various CVD websites. These searches were further updated in March 2024. Additionally, we reviewed the reference lists of the final selected research articles to identify any additional relevant literature. Findings: A total of 2307 records were identified during the process of conducting the study, consisting of 564 entries from external sites like arXiv and 1743 records found through database searching. After 430 duplicate articles were eliminated, 1877 items that remained were screened for relevancy. In this stage, 1241 articles remained for additional review after 158 irrelevant articles and 478 articles with insufficient data were removed. 355 articles were eliminated for being inaccessible, 726 for being written in a language other than English, and 281 for not having undergone peer review. Consequently, 121 studies were deemed suitable for inclusion in the qualitative synthesis. At the intersection of CVD, AI, and precision medicine, we found important scientific findings in our scoping review. Intricate pattern extraction from large, complicated genetic datasets is a skill that AI algorithms excel at, allowing for accurate disease diagnosis and CVD risk prediction. Furthermore, these investigations have uncovered unique genetic biomarkers linked to CVD, providing insight into the workings of the disease and possible treatment avenues. The construction of more precise predictive models and personalised treatment plans based on the genetic profiles of individual patients has been made possible by the revolutionary advancement of CVD risk assessment through the integration of AI and genomics. Interpretation: The systematic methodology employed ensured the thorough examination of available literature and the inclusion of relevant studies, contributing to the robustness and reliability of the study's findings. Our analysis stresses a crucial point in terms of the adaptability and versatility of AI solutions. AI algorithms designed in non-CVD domains such as in oncology, often include ideas and tactics that might be modified to address cardiovascular problems. Funding: No funding received.

Indexed as

Artificial intelligenceCardiovascular diseasesDeep learningPersonalised medicinePrecision medicine

Identifiers

PMID38846068
PMCPMC11154124

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.